Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $640.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Aclaris Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Aclaris Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kolbeck Roland Wilhelm | Chief Scientific Officer | 23,990 | Aug 4, 2026 | 2 |
| Schiff Andrew N | Director | 25,540 | Jun 8, 2026 | 1 |
| Milano Vincent | Director | 28,896 | Jun 8, 2026 | 1 |
| Gowen Maxine | Director | 33,334 | Jun 8, 2026 | 1 |
| Mehra Anand | Director | 726,403 | Jun 8, 2026 | 1 |
| Molineaux Christopher P. | Director | 69,536 | Jun 8, 2026 | 1 |
| Humphries William D. | Director | 45,105 | Jun 8, 2026 | 1 |
| Hall Jesse Wayne | Chief Medical Officer | 27,045 | May 5, 2026 | 2 |
| Leonard Braden Michael | 10% Owner | 13,950,000Indirect | Apr 27, 2026 | 1 |
| Balthaser Kevin | Chief Financial Officer | 187,453 | Mar 3, 2026 | 5 |
| Walker Neal | CEO | 1,543,886 | Feb 6, 2026 | 3 |
| Loerop James | Chief Business Officer | 192,260 | Feb 6, 2026 | 5 |
| Davis Hugh M. | President and COO | 45,425 | Feb 6, 2026 | 3 |
| Monahan Joseph | Chief Scientific Officer | 265,662 | Mar 4, 2025 | 0 |
| Powell Andrew Kenneth William | Director | 33,523 | Jun 4, 2024 | 0 |
| Reasons Bryan M. | Director | 28,732 | Jun 4, 2024 | 0 |
| Manion Douglas J. | Pres and CEO | 41,813 | Jan 3, 2024 | 0 |
| Cawkwell Gail | Chief Medical Officer | 9,593 | Jul 5, 2023 | 0 |
| Ruffo Frank | Chief Financial Officer | 201,883 | Mar 14, 2022 | 0 |
| Ali-Jackson Kamil | Chief Legal Officer | 160,214 | Jan 5, 2022 | 0 |
| Tananbaum James B. | 10% Owner | 8,276Indirect | Nov 3, 2021 | 0 |
| Foresite Capital Management III, LLC | 10% Owner | 8,276Indirect | Nov 3, 2021 | 0 |
| Foresite Capital Fund III, L.P. | 10% Owner | 8,276Indirect | Nov 3, 2021 | 0 |
| Foresite Capital Fund IV, L.P. | 10% Owner | 8,276Indirect | Nov 3, 2021 | 0 |
| Foresite Capital Management IV, LLC | 10% Owner | 8,276Indirect | Nov 3, 2021 | 0 |
| Foresite Capital Fund V, L.P. | 10% Owner | 8,276Indirect | Nov 3, 2021 | 0 |
| Foresite Capital Management V, LLC | 10% Owner | 8,276Indirect | Nov 3, 2021 | 0 |
| Gordon David N. | Chief Medical Officer | 147,447 | Jul 14, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 (view filing) | Apr 23 | 4 days | Leonard Braden Michael10% Owner | SSale | −300.0K | $4.53 | −$1.36M | −2.1%13.9M after | |
| Nov 20, 2024 (view filing) | Nov 19 | 1 day | Mehra AnandDirector | PPurchase | +666.7K | $2.25 | +$1.50M | +1,537.4%710.0K after | |
| Aug 5, 2024 (view filing) | Aug 2-5 | 3 days | Leonard Braden Michael10% Owner | PPurchase | +373.6K | $1.26 | +$471.6K | +2.7%14.3M after | 2 lots |
| Jul 31, 2024 (view filing) | Jul 30-31 | 1 day | Leonard Braden Michael10% Owner | PPurchase | +273.7K | $1.31 | +$358.8K | +2.0%13.9M after | 2 lots |
| Jul 22, 2024 (view filing) | Jul 18-22 | 4 days | Leonard Braden Michael10% Owner | PPurchase | +154.7K | $1.30 | +$201.7K | +1.2%13.6M after | 3 lots |
| Jul 5, 2024 (view filing) | Jul 2-5 | 3 days | Leonard Braden Michael10% Owner | PPurchase | +352.4K | $1.15 | +$405.8K | +2.7%13.4M after | 3 lots |
| Jul 1, 2024 (view filing) | Jun 27-Jul 1 | 4 days | Leonard Braden Michael10% Owner | PPurchase | +1.54M | $1.13 | +$1.74M | +13.4%13.1M after | 4 lots |
| Jun 18, 2024 (view filing) | Jun 14-18 | 4 days | Leonard Braden Michael10% Owner | PPurchase | +545.0K | $1.16 | +$629.6K | +5.0%11.6M after | 3 lots |
| Jun 13, 2024 (view filing) | Jun 11-13 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +1.61M | $1.11 | +$1.78M | +17.1%11.0M after | 4 lots |
| Mar 5, 2024 (view filing) | Mar 1-4 | 4 days | Powell Andrew Kenneth WilliamDirector | PPurchase | +14.5K | $1.24 | +$18.0K | +101.0%28.9K after | 2 lots |
| Oct 25, 2023 (view filing) | Oct 23 | 2 days | Monahan JosephChief Scientific Officer | SSale | −6.00K | $5.08 | −$30.5K | −4.4%129.7K after | 10b5-1 |
| Sep 7, 2023 (view filing) | Sep 6 | 1 day | Balthaser KevinChief Financial Officer | PPurchase | +9.49K | $7.90 | +$75.0K | +158.9%15.5K after | |
| Aug 28, 2023 (view filing) | Aug 28 | Same day | Loerop JamesChief Business Officer | PPurchase | +14.7K | $6.80 | +$100.0K | +210.6%21.7K after | |
| Aug 22, 2023 (view filing) | Aug 21 | 1 day | Monahan JosephChief Scientific Officer | SSale | −6.00K | $7.32 | −$43.9K | −4.2%135.7K after | 10b5-1 |
| Jun 22, 2023 (view filing) | Jun 20 | 2 days | Monahan JosephChief Scientific Officer | SSale | −6.00K | $10.28 | −$61.7K | −4.1%141.7K after | 10b5-1 |
| Mar 17, 2023 (view filing) | Mar 17 | Same day | Manion Douglas J.Pres and CEO | PPurchase | +6.30K | $7.86 | +$49.5K | +96.9%12.8K after | |
| Mar 9, 2023 (view filing) | Mar 9 | Same day | Manion Douglas J.Pres and CEO | PPurchase | +6.50K | $7.74 | +$50.3K | New position6.50K after | |
| Mar 3, 2023 (view filing) | Mar 2-3 | 1 day | Walker NealDirector | SSale | −59.2K | $12.50 | −$740.7K | −4.4%1.27M after | 2 lots |
| Mar 3, 2023 (view filing) | Mar 2-3 | 1 day | Monahan JosephChief Scientific Officer | SSale | −30.8K | $12.51 | −$385.6K | −17.3%147.7K after | 2 lots |
| Mar 3, 2023 (view filing) | Mar 2-3 | 1 day | Balthaser KevinChief Financial Officer | SSale | −1.89K | $12.45 | −$23.6K | −26.5%5.26K after | 2 lots |
| Feb 17, 2023 (view filing) | Feb 15 | 2 days | Monahan JosephChief Scientific Officer | SSale | −5.00K | $13.06 | −$65.3K | −5.2%91.4K after | |
| Feb 10, 2023 (view filing) | Feb 8 | 2 days | Loerop JamesChief Business Officer | SSale | −4.27K | $13.89 | −$59.3K | −37.9%6.98K after | |
| Feb 3, 2023 (view filing) | Feb 1-2 | 2 days | Walker NealDirector | SSale | −30.0K | $16.67 | −$500.0K | −2.5%1.18M after | 5 lots |
| Jan 4, 2023 (view filing) | Jan 3-4 | 1 day | Walker NealDirector | SSale | −40.0K | $15.12 | −$604.7K | −3.2%1.21M after | 3 lots |
| Dec 16, 2022 (view filing) | Dec 15 | 1 day | Monahan JosephChief Scientific Officer | SSale | −5.00K | $15.88 | −$79.4K | −4.9%96.4K after | |
| Nov 14, 2022 (view filing) | Nov 10-14 | 4 days | Schiff Andrew NDirector | SSale | −53.9K | $17.05 | −$919.5K | −11.0%434.5K after | 3 lots |
| Oct 26, 2022 (view filing) | Oct 24-26 | 2 days | Schiff Andrew NDirector | SSale | −41.2K | $17.01 | −$700.5K | −7.8%488.4K after | 3 lots |
| Oct 19, 2022 (view filing) | Oct 17-18 | 2 days | Schiff Andrew NDirector | SSale | −52.0K | $16.57 | −$862.2K | −8.9%529.6K after | 2 lots |
| Oct 19, 2022 (view filing) | Oct 17 | 2 days | Monahan JosephChief Scientific Officer | SSale | −5.00K | $15.98 | −$79.9K | −4.7%101.4K after | |
| Oct 11, 2022 (view filing) | Oct 7 | 4 days | Schiff Andrew NDirector | SSale | −7.32K | $16.16 | −$118.4K | −1.2%581.6K after | |
| Oct 6, 2022 (view filing) | Oct 4-6 | 2 days | Schiff Andrew NDirector | SSale | −45.5K | $16.45 | −$749.1K | −7.2%588.9K after | 2 lots |
| Jun 21, 2022 (view filing) | Jun 17 | 4 days | Schiff Andrew NDirector | SSale | −19.6K | $15.14 | −$296.2K | −100.0%0 after | |
| Apr 25, 2022 (view filing) | Apr 21-25 | 4 days | Walker NealPresident and CEO | SSale | −70.0K | $15.15 | −$1.06M | −5.3%1.25M after | 3 lots |
| Apr 20, 2022 (view filing) | Apr 18 | 2 days | Monahan JosephChief Scientific Officer | SSale | −30.0K | $16.28 | −$488.4K | −22.0%106.4K after | |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Walker NealPresident and CEO | SSale | −56.3K | $15.91 | −$895.8K | −4.1%1.32M after | |
| Mar 14, 2022 (view filing) | Mar 10 | 4 days | Ruffo FrankChief Financial Officer | SSale | −12.8K | $15.55 | −$199.4K | −6.0%201.9K after | |
| Mar 14, 2022 (view filing) | Mar 10 | 4 days | Monahan JosephChief Scientific Officer | SSale | −27.2K | $15.71 | −$426.8K | −16.6%136.4K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Monahan JosephChief Scientific Officer | SSale | −383 | $12.68 | −$4.86K | −0.4%87.3K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Ruffo FrankChief Financial Officer | SSale | −1.39K | $12.66 | −$17.6K | −0.8%172.4K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Walker NealPresident and CEO | SSale | −3.60K | $12.66 | −$45.5K | −0.3%1.24M after | |
| Jul 14, 2021 (view filing) | Jul 13 | 1 day | Gordon David N.Chief Medical Officer | SSale | −2.63K | $16.98 | −$44.7K | −1.8%147.4K after |